For research. With context.

Search Peptipedia.

Ask a question or explore a peptide. Read a plain-language explanation, then follow its sources for more detail.

Results for “LL-37”

4 source papers

Original source papers

2025 AugThe lancet. Diabetes & endocrinology
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al.
PubMed · PMID 40609566Randomized Controlled Trial · Clinical Trial, Phase II
2022 Sep 6Cell metabolism
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC et al.
PubMed · PMID 35985340Journal article
2024 Dec 15European journal of pharmacology
The power of three: Retatrutide's role in modern obesity and diabetes therapy.
Abdul-Rahman T, Roy P, Ahmed FK et al.
PubMed · PMID 39515565Review
2024 JulNature medicine
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP et al.
PubMed · PMID 38858523Randomized Controlled Trial · Clinical Trial, Phase II